FDA rule would give opening to generic drug plaintiffs

WASHINGTON – Following two U.S. Supreme Court decisions that shut the door on state-law failure-to-warn and design-defect claims over generic drugs, the Food and Drug Administration is taking steps that could ultimately open a window for plaintiffs. The agency has stated its intention to issue a proposed rule that would loosen the federal restriction on ...